Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients

Gilead Sciences, Inc. (GILD: Quote) reported data from two Phase 2 studies and a compassionate access study, wherin a regimen containing once-daily Sovaldi 400 mg was administered to treat chronic hepatitis C virus or HCV infection in patients with advanced liver disease.

The first study, named Study GS-US-334-0125, is an ongoing open-label Phase 2 trial assessing HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin or RBV was administered for 48 weeks or to a deferred treatment arm in which this regimen was started after a 24-week observation period.

Out of the 22 patients who completed 24 weeks of therapy, 95 percent achieved virologic suppression on treatment. Further, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm; and 80% of participants were treatment-experienced

Study GS-US-334-0126, was a single-arm open-label Phase 2 study in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV. The majority of patients had genotype 1-HCV infection and 88 percent were treatment-experienced. According to the company, seventy percent of patients in this study achieved SVR12.

Register
To receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.